anti-silencing function 1A histone chaperoneGenealiases: CGI-98 · CIA · HSPC146
Q-omics provides the consensus-scored ASF1A profile across patient tissues and cancer cell-line models. ASF1A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ASF1A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ASF1A protein abundance shows 26,780 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRC, and LSCC as cancer lineages where ASF1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASF1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASF1A survival associations across molecular data types. ASF1A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASF1A RNA expression–survival associations across cancer types. High ASF1A expression shows unfavorable associations in LIHC, ESCA, SCLC, ACC and KIRP, but favorable associations in LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ASF1A RNA expression.
This table summarizes ASF1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ASF1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASF1A shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in HNSC, LIHC and CHOL. The KIRC box plot shows higher ASF1A RNA expression in normal versus tumor tissue (log2 FC = −0.703, t-test p < 0.001).
This table shows molecular features associated with ASF1A in patient tissues and cancer cell lines. In patient samples, ASF1A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASF1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
